<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04331912</url>
  </required_header>
  <id_info>
    <org_study_id>NEN_2019</org_study_id>
    <nct_id>NCT04331912</nct_id>
  </id_info>
  <brief_title>PFS and OS of Patients With Advanced Neuroendocrine Cancer (NEN) After Systemic Treatment</brief_title>
  <official_title>Outcomes of Patients With Advanced Neuroendocrine Cancer (NEN) Treated With Systemic Treatment: Somatostatin Analogues, Molecular Targeted Therapy, Chemotherapy and Peptide Radioisotope Therapy - a Retrospective Analysis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Warmia and Mazury</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Warmia and Mazury</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective study. The analysis includes patients with advanced neuroendocrine
      cancer (NEN) treated with systemic therapy, because of inoperable primary tumor or/and
      metastasis, clinical, imaging, biochemical disease progression and no standard method of
      treatment hormone overproduction symptoms. The data of patients with advanced NEN with
      histopathological confirmation is collected from medical records. The progression-free
      survival (PFS), overall survival (OS) and influence of various factors on survival will be
      estimated. The research will be conducted for above 3 years on planned group 1500 patients.
      The aim of the study is to estimate median OS and PFS in advanced NEN patients treated with
      different schedule of systemic treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective study. The analysis includes patients with advanced neuroendocrine
      cancer (NEN) treated with systemic therapy, because of inoperable primary tumor or/and
      metastasis, clinical, imaging, biochemical disease progression and no standard method of
      treatment hormone overproduction symptoms. Systemic treatment including: somatostatin
      receptor analogues, molecular targeted therapy (sunitinib and everolimus), chemotherapy and
      peptide radioisotope therapy (Peptide Receptor Radionuclide Therapy). The data of patients
      with advanced NEN with histopathological or/and clinical or/and biochemical confirmation is
      collected from medical records. Neuroendocrine cancer from digestive system, respiratory
      system and another rarely occurring cancer including cancer connected with genetic syndromes
      like: MEN1, MEN2, VHL, NF1, SDHx will be included. The progression-free survival (PFS),
      overall survival (OS) and influence of various factors on survival will be estimated.
      Analyzed factors: age, sex, ethnicity, specific symptoms at the time of diagnosis, carcinoid
      heart disease, level of 5HIAA in DZM, level of CgA, liver test, size of tumor, cell
      differentiation of tumor based on Ki-67 index, liver metastases. The research will be
      conducted for above 3 years since July 2019 till December 2022 on planned group 1500
      patients. The aim of the study is to estimate median OS and PFS in advanced NEN patients
      treated with different schedule of systemic treatment. The second goal is to create clinical
      practice recommendation based on potential prognostic factors of OS and PFS due to type of
      therapy in different NEN subgroups.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PFS - Progression Free Survival</measure>
    <time_frame>7 years</time_frame>
    <description>the time from the start of systemic treatment date to the date of first documented disease progression (event: disease progression - DP, based on RECIST, death, adverse events, which provide to disqualification from further therapy). Patients without progression at the time of analysis will be censored.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OS - Overall Survival</measure>
    <time_frame>7 years</time_frame>
    <description>is defined as the time from the start of systemic treatment date to the date of death due to any cause or the date of last contact (censored observation) at the date of data cut-off.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Log-rank test</measure>
    <time_frame>7 years</time_frame>
    <description>assessment of differences in survival of patients between subgroups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cox proportional-hazards model</measure>
    <time_frame>7 years</time_frame>
    <description>uni- and multivariate analyses used for investigating the association between the survival time of patients and prognostic factors</description>
  </secondary_outcome>
  <enrollment type="Actual">57</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study is planned on a group 1500 patients with advanced, histopathologically confirmed
        neuroendocrine neoplasms (NEN) treated with different schedule of systemic treatment
        including: somatostatin receptor analogues, molecular targeted therapy (sunitinib or
        everolimus), chemotherapy using different therapeutic regimens and peptide receptor
        radioisotope therapy (Peptide Receptor Radionuclide Therapy).

        Research on NEN patients will include the following groups of patients:

          1. NEN from digestive system,

          2. respiratory system;

          3. Other NEN tumours including PPGL, cancer of known primary and very rare NEN tumours
             like gynecological or urological primary NET.

          4. NEN connected with genetic syndromes like: MEN1, MEN2, VHL, NF1, SDHx.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults ≥18 years old, male or female,

          -  Patients with histopathological confirmation of advanced neuroendocrine cancer (NEN),

          -  Patients with NETG1, NETG2 based on Ki-67,

          -  Patients with diagnosed NEN, who did not receive prior treatment and were qualified to
             systemic treatment,

          -  Patients with advanced NEN who previously received first-line systemic therapy or
             second-line systemic therapy,

          -  Patients with advanced, inoperable NEN cancer before the treatment, during the
             treatment and after the treatment regardless of lines of systemic therapy,

          -  Patients with diagnosed NEN and performance status (PS) ≤3 according to ECOG/WHO
             classification, who received systemic therapy.

        Exclusion Criteria:

          -  Patients without histopathological confirmation of neuroendocrine carcinoma (NEN),

          -  Patients with diagnosed another type of cancer or benign tumor confirmed in
             histopathological examination,

          -  Patients treated prior with intention to treat (ITT),

          -  Patients with residual disease in further clinical follow-up without active systemic
             treatment,

          -  Patients with advanced, progressive and poor performance status, who were disqualified
             from further systemic treatment,

          -  Patients, who finished treatment during first month or their further disease process
             was unknown.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>87 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Warmia and Mazury in Olsztyn</name>
      <address>
        <city>Olsztyn</city>
        <state>Warmińsko-Mazurskie</state>
        <zip>10-082</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <results_reference>
    <citation>Modlin IM, Shapiro MD, Kidd M. Siegfried Oberndorfer: origins and perspectives of carcinoid tumors. Hum Pathol. 2004 Dec;35(12):1440-51.</citation>
    <PMID>15619202</PMID>
  </results_reference>
  <results_reference>
    <citation>Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008 Jan;9(1):61-72. doi: 10.1016/S1470-2045(07)70410-2. Review.</citation>
    <PMID>18177818</PMID>
  </results_reference>
  <results_reference>
    <citation>Modlin IM, Champaneria MC, Bornschein J, Kidd M. Evolution of the diffuse neuroendocrine system--clear cells and cloudy origins. Neuroendocrinology. 2006;84(2):69-82. Epub 2006 Nov 9. Review.</citation>
    <PMID>17106184</PMID>
  </results_reference>
  <results_reference>
    <citation>Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003 Feb 15;97(4):934-59.</citation>
    <PMID>12569593</PMID>
  </results_reference>
  <results_reference>
    <citation>Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci. 2004 Apr;1014:13-27. Review.</citation>
    <PMID>15153416</PMID>
  </results_reference>
  <results_reference>
    <citation>Greene FL. TNM staging for malignancies of the digestive tract: 2003 changes and beyond. Semin Surg Oncol. 2003;21(1):23-9. Review.</citation>
    <PMID>12923913</PMID>
  </results_reference>
  <results_reference>
    <citation>Klöppel G, Rindi G, Perren A, Komminoth P, Klimstra DS. The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows Arch. 2010 Jun;456(6):595-7. doi: 10.1007/s00428-010-0924-6. Epub 2010 Apr 27.</citation>
    <PMID>20422210</PMID>
  </results_reference>
  <results_reference>
    <citation>Washington MK, Tang LH, Berlin J, Branton PA, Burgart LJ, Carter DK, Compton CC, Fitzgibbons PL, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE; Members of the Cancer Committee, College of American Pathologists. Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the small intestine and ampulla. Arch Pathol Lab Med. 2010 Feb;134(2):181-6. doi: 10.1043/1543-2165-134.2.181.</citation>
    <PMID>20121604</PMID>
  </results_reference>
  <results_reference>
    <citation>Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007 Oct;451(4):757-62. Epub 2007 Aug 3.</citation>
    <PMID>17674042</PMID>
  </results_reference>
  <results_reference>
    <citation>Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gönen M, Jensen RT, Kidd M, Kulke MH, Lloyd RV, Moran C, Moss SF, Oberg K, O'Toole D, Rindi G, Robert ME, Suster S, Tang LH, Tzen CY, Washington MK, Wiedenmann B, Yao J. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol. 2010 Mar;34(3):300-13. doi: 10.1097/PAS.0b013e3181ce1447.</citation>
    <PMID>20118772</PMID>
  </results_reference>
  <results_reference>
    <citation>Modlin IM, Gustafsson BI, Pavel M, Svejda B, Lawrence B, Kidd M. A nomogram to assess small-intestinal neuroendocrine tumor ('carcinoid') survival. Neuroendocrinology. 2010;92(3):143-57. doi: 10.1159/000319784. Epub 2010 Aug 23.</citation>
    <PMID>20733279</PMID>
  </results_reference>
  <results_reference>
    <citation>Delle Fave G, O'Toole D, Sundin A, Taal B, Ferolla P, Ramage JK, Ferone D, Ito T, Weber W, Zheng-Pei Z, De Herder WW, Pascher A, Ruszniewski P; Vienna Consensus Conference participants. ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. Neuroendocrinology. 2016;103(2):119-24. doi: 10.1159/000443168. Epub 2016 Jan 19.</citation>
    <PMID>26784901</PMID>
  </results_reference>
  <results_reference>
    <citation>Niederle B, Pape UF, Costa F, Gross D, Kelestimur F, Knigge U, Öberg K, Pavel M, Perren A, Toumpanakis C, O'Connor J, O'Toole D, Krenning E, Reed N, Kianmanesh R; Vienna Consensus Conference participants. ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum. Neuroendocrinology. 2016;103(2):125-38. doi: 10.1159/000443170. Epub 2016 Jan 12.</citation>
    <PMID>26758972</PMID>
  </results_reference>
  <results_reference>
    <citation>Ramage JK, De Herder WW, Delle Fave G, Ferolla P, Ferone D, Ito T, Ruszniewski P, Sundin A, Weber W, Zheng-Pei Z, Taal B, Pascher A; Vienna Consensus Conference participants. ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms. Neuroendocrinology. 2016;103(2):139-43. doi: 10.1159/000443166. Epub 2016 Jan 5.</citation>
    <PMID>26730835</PMID>
  </results_reference>
  <results_reference>
    <citation>Pape UF, Niederle B, Costa F, Gross D, Kelestimur F, Kianmanesh R, Knigge U, Öberg K, Pavel M, Perren A, Toumpanakis C, O'Connor J, Krenning E, Reed N, O'Toole D; Vienna Consensus Conference participants. ENETS Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding Goblet Cell Carcinomas). Neuroendocrinology. 2016;103(2):144-52. doi: 10.1159/000443165. Epub 2016 Jan 5.</citation>
    <PMID>26730583</PMID>
  </results_reference>
  <results_reference>
    <citation>Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, Kos-Kudla B, Kwekkeboom D, Rindi G, Klöppel G, Reed N, Kianmanesh R, Jensen RT; Vienna Consensus Conference participants. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2016;103(2):153-71. doi: 10.1159/000443171. Epub 2016 Jan 5.</citation>
    <PMID>26742109</PMID>
  </results_reference>
  <results_reference>
    <citation>Pavel M, O'Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, Krenning E, Knigge U, Salazar R, Pape UF, Öberg K; Vienna Consensus Conference participants. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology. 2016;103(2):172-85. doi: 10.1159/000443167. Epub 2016 Jan 5.</citation>
    <PMID>26731013</PMID>
  </results_reference>
  <results_reference>
    <citation>Garcia-Carbonero R, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B, Sedlackova E, Toumpanakis C, Anlauf M, Cwikla JB, Caplin M, O'Toole D, Perren A; Vienna Consensus Conference participants. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology. 2016;103(2):186-94. doi: 10.1159/000443172. Epub 2016 Jan 5.</citation>
    <PMID>26731334</PMID>
  </results_reference>
  <results_reference>
    <citation>Peczkowska M, Erlic Z, Hoffmann MM, Furmanek M, Cwikla J, Kubaszek A, Prejbisz A, Szutkowski Z, Kawecki A, Chojnowski K, Lewczuk A, Litwin M, Szyfter W, Walter MA, Sullivan M, Eng C, Januszewicz A, Neumann HP. Impact of screening kindreds for SDHD p.Cys11X as a common mutation associated with paraganglioma syndrome type 1. J Clin Endocrinol Metab. 2008 Dec;93(12):4818-25. doi: 10.1210/jc.2008-1290. Epub 2008 Sep 30.</citation>
    <PMID>18826997</PMID>
  </results_reference>
  <results_reference>
    <citation>Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008 Mar 10;26(8):1364-70. doi: 10.1200/JCO.2007.12.9791. Review.</citation>
    <PMID>18323559</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 31, 2020</study_first_submitted>
  <study_first_submitted_qc>March 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Warmia and Mazury</investigator_affiliation>
    <investigator_full_name>Jaroslaw B. Cwikla, MD, PhD, Professor UWM</investigator_full_name>
    <investigator_title>MD, PhD, Professor UWM</investigator_title>
  </responsible_party>
  <keyword>NEN-neuroendocrine cancer, overall survival</keyword>
  <keyword>OS - overall survival</keyword>
  <keyword>PFS - progression-free survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

